Business Context and Reporting Period
Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) filed this Form 8-K on March 7, 2013, to report unregistered sales of equity securities. The company is a Delaware corporation headquartered in Parsippany, New Jersey.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity transaction.
Material Changes
On March 7, 2013, the Company issued an aggregate of 53,741 shares of common stock upon the exercise of warrants by venture funds affiliated with Sanderling Ventures. These warrants were originally issued in 2009 and 2010 in connection with private placements of convertible promissory notes. The exercise was conducted on a cashless basis pursuant to the warrant provisions, meaning the Company received no proceeds from the issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The transaction was executed in reliance on exemptions under Section 4(2) of the Securities Act of 1933 and applicable state laws, as the shares were issued to accredited investors without registration. Further details regarding the purchasers are referenced in a Form 4 filed on March 11, 2013.
Investor Verification Checklist
- Verify the total number of shares issued (53,741) and the date of issuance (March 7, 2013).
- Confirm that the transaction was a cashless exercise resulting in zero proceeds to the Company.
- Review the Form 4 filed on March 11, 2013, for details on the beneficial ownership changes by Sanderling Ventures affiliates.
- Note that this filing does not contain updated financial performance data or forward-looking guidance.